“The 2nd generation COC with the rogestogens levonorgestrel and norgestimate confer a three imes increased risk of venous thrombosis, while COC with 3rd desogestrel and gestodene) and 4th (drospirenone) generation rogestogens increase the risk at least six times [1–3].”